Sporadic inclusion body myositis (sIBM) is the most common myopathy after age 45. It is a progressive disease with a severe prognosis leading to wheelchair confinement in ten years from the onset. So far no treatment has yet been shown to slow or stop the progression of the disease. sIBM involves both inflammatory and degenerative characteristics, and the true primary pathogenesis of the disease remains a subject of intense debate. From a cellular point of view, it has been shown that although satellite cells (SC) proliferation is normal in IBM patients, their differentiation ability is impaired, leading to muscle regeneration program failure.